Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
NSC Norfolk Southern Corp
WM Waste Management Inc
ITOS Iteos Therapeutics Inc
CCLD CareCloud Inc
JEF Jefferies Financial Group Inc
RSASF Resaas Services Inc
VRNT Verint Systems Inc
TRHC Tabula Rasa HealthCare Inc
ILMN Illumina Inc

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Day's Change
-10.86 (-1.39%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 556,572 shares is on pace to be lower than REGN's 10-day average volume of 724,147 shares.


Arista Networks stock muted as earnings clear analysts' low bar

8:03 am ET November 1, 2022 (MarketWatch)

By Wallace Witkowski

Revenue comes in at $1.06 billion, about midpoint of its outlook, as analysts had forecast $856.1 million

Arista Networks Inc. shares searched for direction in the extended session Monday after the cloud-software and data-center supplier's earnings and outlook topped the relatively low Wall Street consensus.

Arista (ANET) shares shifted between slight gains and losses after hours, and were last down 1.6%, following a 0.5% decline in the regular session to close at $120.86. The company's share price is down 16% year to date, versus 19% decline by the S&P 500 index and a 30% drop in the tech-heavy Nasdaq Composite Index over that period.

The company reported third-quarter net income of $354 million, or $1.13 a share, compared with $224.3 million, or 70 cents a share, in the year-ago period. Adjusted earnings, which exclude stock-based compensation expenses and other items, were $1.25 a share, compared with 74 cents a share in the year-ago period. Per-share amounts account for last year's four-to-one stock split announced back in November.

Revenue rose to $1.06 billion from $748.7 million in the year-ago quarter.

Analysts surveyed by FactSet had forecast earnings of $1.04 a share on revenue of $856.1 million, based on Arista's forecast of $1.03 billion to $1.08 billion.

For the fourth quarter, Arista forecast revenue between $1.18 billion and $1.2 billion, while analysts forecast revenue of $1.09 billion.

-Wallace Witkowski


(END) Dow Jones Newswires

November 01, 2022 08:03 ET (12:03 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.